Base de dados : LILACS
Pesquisa : D03.383.129.539 [Categoria DeCS]
Referências encontradas : 52 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 52 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-991375
Autor: Enríquez, Andrés; Baranchuk, Adrian; Corbalán, Ramón.
Título: Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión / Management of bleeding associated with direct oral anticoagulants: update on reversal strategies
Fonte: Rev. méd. Chile;147(1):73-82, 2019. tab, graf.
Idioma: es.
Resumo: Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial hemorrhage. Specific reversal agents have been developed in recent years. Namely, idarucizumab, a specific antidote for dabigatran, is currently approved in most countries. Andexanet, which reverses factor Xa inhibitors, has been recently approved by the FDA, and ciraparantag, a universal antidote targeted to reverse all DOACs, is still under investigation. In this review we provide an update on the pharmacology of DOACs, the risk of hemorrhagic complications associated with their use, the measurement of their anticoagulant effect and the reversal strategies in case of DOAC-associated bleeding.
Descritores: Fatores de Coagulação Sanguínea/uso terapêutico
Antitrombinas/administração & dosagem
Antitrombinas/efeitos adversos
Anticorpos Monoclonais Humanizados/uso terapêutico
Hemorragia/induzido quimicamente
Hemorragia/terapia
-Pirazóis/administração & dosagem
Pirazóis/efeitos adversos
Piridinas/administração & dosagem
Piridinas/efeitos adversos
Piridonas/administração & dosagem
Piridonas/efeitos adversos
Tiazóis/administração & dosagem
Tiazóis/efeitos adversos
Administração Oral
Fatores de Risco
Rivaroxabana/administração & dosagem
Rivaroxabana/efeitos adversos
Dabigatrana/administração & dosagem
Dabigatrana/efeitos adversos
Antídotos/uso terapêutico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CL1.1 - Biblioteca Central


  2 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886915
Autor: BOVI, THAÍS S; ZALUSKI, RODRIGO; ORSI, RICARDO O.
Título: Toxicity and motor changes in Africanized honey bees (Apis mellifera L) exposed to fipronil and imidacloprid
Fonte: An. acad. bras. ciênc;90(1):239-245, Mar. 2018. tab.
Idioma: en.
Resumo: ABSTRACT This study evaluated the in vitro toxicity and motor activity changes in African-derived adult honey bees (Apis mellifera L.) exposed to lethal or sublethal doses of the insecticides fipronil and imidacloprid. Mortality of bees was assessed to determine the ingestion and contact lethal dose for 24 h using probit analysis. Motor activities in bees exposed to lethal (LD50) and sublethal doses (1/500th of the lethal dose) of both insecticides were evaluated in a behavioral observation box at 1 and 4 h. Ingestion and contact lethal doses of fipronil were 0.2316 ? 0.0626 and 0.0080 ? 0.0021 μg/bee, respectively. Ingestion and contact lethal doses of imidacloprid were 0.1079 ? 0.0375 and 0.0308 ? 0.0218 μg/bee, respectively. Motor function of bees exposed to lethal doses of fipronil and imidacloprid was impaired; exposure to sublethal doses of fipronil but not imidacloprid impaired motor function. The insecticides evaluated in this study were highly toxic to African-derived A. mellifera and caused impaired motor function in these pollinators.
Descritores: Pirazóis/toxicidade
Abelhas/efeitos dos fármacos
Neonicotinoides/toxicidade
Inseticidas/toxicidade
Atividade Motora/efeitos dos fármacos
Nitrocompostos/toxicidade
-Abelhas/fisiologia
Comportamento Animal/efeitos dos fármacos
Dose Letal Mediana
Limites: Animais
Responsável: BR1.1 - BIREME


  3 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-547322
Autor: Crippa, José Alexandre S; Zuardi, Antonio Waldo; Hallak, Jaime E C.
Título: Uso terapêutico dos canabinoides em psiquiatria: [revisão] / Therapeutical use of the cannabinoids in psychiatry: [review]
Fonte: Rev. bras. psiquiatr;32(supl.1):556-566, maio 2010. graf, tab.
Idioma: pt.
Resumo: OBJETIVO: Revisar os principais avanços no potencial uso terapêutico de alguns compostos canabinoides em psiquiatria. MÉTODO: Foi realizada busca nos bancos de dado PubMed, SciELO e Lilacs e identificados estudos e revisões da literatura sobre o uso terapêutico dos canabinoides em psiquiatria, em particular canabidiol, rimonabanto, Δ9-tetraidrocanabinol e seus análogos. RESULTADOS: O canabidiol demonstrou apresentar potencial terapêutico como antipsicótico, ansiolítico, antidepressivo e em diversas outras condições. O Δ9-tetraidrocanabinol e seus análogos demonstraram efeitos ansiolíticos, na dependência de cannabis, bem como adjuvantes no tratamento de esquizofrenia, apesar de ainda carecerem de mais estudos. O rimonabanto demonstrou eficácia no tratamento de sintomas subjetivos e fisiológicos da intoxicação pela cannabis e como adjuvante no tratamento do tabagismo. Os potenciais efeitos colaterais, de induzir depressão e ansiedade limitaram o uso clínico deste antagonista CB1. CONCLUSÃO: Os canabinoides têm demonstrado que podem ter amplo interesse terapêutico em psiquiatria, porém mais estudos controlados são necessários para confirmar estes achados e determinar a segurança destes compostos.

OBJECTIVE: To review the main advances related to the potential therapeutic use of cannabinoid compounds in psychiatry. METHOD: A search was performed in the online databases PubMed, ScieELO, and Lilacs for studies and literature reviews concerning therapeutic applications of cannabinoids in psychiatry, especially cannabidiol, rimonabant, Δ9-tetrahydrocannabinol, and their analogues. RESULTS: Cannabidiol was found to have therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in other conditions. Δ9-tetrahydrocannabinol and its analogues were shown to have anxiolytic effects in the treatment of cannabis dependence and to function as an adjuvant in the treatment of schizophrenia, although additional studies are necessary to support this finding. Rimonabant was effective in the treatment of the subjective and physiological symptoms of cannabis intoxication and functioned as an adjuvant in the treatment of tobacco addiction. The potential to induce adverse reactions such as depression and anxiety restrained the clinical use of this CB1 antagonist. CONCLUSION: Cannabinoids may be of great therapeutic interest to psychiatry; however, further controlled trials are necessary to confirm the existing findings and to establish the safety of such compounds.
Descritores: Piperidinas/uso terapêutico
Psicotrópicos/uso terapêutico
Pirazóis/uso terapêutico
Dronabinol/uso terapêutico
Canabidiol/uso terapêutico
Transtornos Mentais/tratamento farmacológico
-Rimonabanto
Limites: Humanos
Animais
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  4 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-623594
Autor: Marr, J. Joseph; Berens, Randolph L.
Título: Hypoxanthine and inosine analogues as chemotherapeutic agents in chagas' disease
Fonte: Mem. Inst. Oswaldo Cruz;83(supl.1):301-307, Nov. 1988.
Idioma: en.
Conferência: Apresentado em: Annual Meeting on Basic Research in Chagas's disease, 15, Apresentado em: Meeting of the Brazilian Society of Protozoology4, Caxambu, 7-10 Nov. 1988.
Descritores: Doença de Chagas/tratamento farmacológico
Inosina/análogos & derivados
Inosina/uso terapêutico
-Pirazóis/uso terapêutico
Tripanossomicidas
Responsável: BR1.1 - BIREME


  5 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1016287
Autor: Cardenas, María Paula.
Título: El apixaban se asocia a un menor riesgo de sangrado que los antagonistas de la vitamina K / Apixaban is associated with a lower risk of bleeding than vitamin K antagonists
Fonte: Evid. actual. práct. ambul;21(2):54-54, jul. 2018. tab..
Idioma: es.
Descritores: Pirazóis/efeitos adversos
Piridonas/efeitos adversos
Vitamina K/antagonistas & inibidores
Tromboembolia Venosa/prevenção & controle
Hemorragia/epidemiologia
Anticoagulantes/efeitos adversos
-Pirazóis/uso terapêutico
Piridonas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Saúde Global
Incidência
Fatores de Risco
Inibidores do Fator Xa/efeitos adversos
Inibidores do Fator Xa/uso terapêutico
Hemorragia/induzido quimicamente
Anticoagulantes/uso terapêutico
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Tipo de Publ: Comentário
Responsável: AR2.1 - Biblioteca Central


  6 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1011652
Autor: Nusrat, Birjees; Siddiqui, Nadeem; Sahu, Meeta; Naim, Mohd. Javed; Shahar Yar, Mohammad; Ali, Ruhi; Ozair, Alam.
Título: Anticonvulsant evaluation of 2-pyrazolines carrying naphthyl moiety: An insight into synthesis and molecular docking study
Fonte: Braz. j. pharm. sci;55:e00249, 2019. tab, graf, ilus.
Idioma: en.
Resumo: A series of N-substituted-3-(napthalen-2-yl)-5-substituted phenyl-4,5-dihydropyrazole-1-carbothioamide derivatives (4a-n) were synthesized with the view of structural requirements of pharmacophore for potential anticonvulsant agents. The synthesized compounds were assayed intraperitoneally (i.p.) and subcutaneously (s.c.) in mice against seizures induced by MES and scPTZ methods, respectively.Neurologic deficit was evaluated by rotarod method. Among the tested compounds, 4g, 4i, 4j and 4n emerged as the most active molecule in the MES model at a dose of 30 mg/kg at 0.5h comparable to standardscarbamazepine and phenytoin. In the scPTZ test,4e and 4l were found to be most active compounds at the lowest dose of 30 mg/kg at 0.5h, in the management of the convulsive disorder. Molecular docking studies of the titled compounds were also donewith 3D crystal structure of human cytosolic branched chain amino transferase (hBCATc) enzyme and compound 4e was found to have five hydrogen bond interactions with the most important active site residues.In neurotoxicity studies, except compounds 4b, 4c, 4h and 4k, rest of the compounds showed no sign of toxicity.
Descritores: Pirazóis/análise
Anticonvulsivantes/análise
-Epilepsia/diagnóstico
Simulação de Acoplamento Molecular/classificação
Limites: Animais
Masculino
Feminino
Camundongos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  7 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-839302
Autor: Chen, B; Hu, N.
Título: Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;50(6):e6141, 2017. graf.
Idioma: en.
Resumo: Cannabinoid type 1 receptor (CB1R) inhibition tends to be one of the promising strategies for the treatment of obesity and other related metabolic disorders. Although CB1R inhibition may cause adverse psychiatric effects including depression and anxiety, the investigation of the role of peripheral CB1R on weight loss and related metabolic parameters are urgently needed. We first explored the effect of rimonabant, a selective CB1R antagonist/inverse agonist, on some metabolic parameters in high fat-diet (HFD)-induced obesity in mice. Then, real-time PCR and electrophysiology were used to explore the contribution of high voltage-activated Ca2+ channels (HVACCs), especially Cav1.1, on rimonabant's effect in skeletal muscle (SM) in HFD-induced obesity. Five-week HFD feeding caused body weight gain, and decreased glucose/insulin tolerance in mice compared to those in the regular diet group (P<0.05), which was restored by rimonabant treatment compared to the HFD group (P<0.05). Interestingly, HVACCs and Cav1.1 were decreased in soleus muscle cells in the HFD group compared to the control group. Daily treatment with rimonabant for 5 weeks was shown to counter such decrease (P<0.05). Collectively, our findings provided a novel understanding for peripheral CB1R's role in the modulation of body weight and glucose homeostasis and highlight peripheral CB1R as well as Cav1.1 in the SM as potential targets for obesity treatment.
Descritores: Glicemia/efeitos dos fármacos
Canais de Cálcio/efeitos dos fármacos
Antagonistas de Receptores de Canabinoides/farmacologia
Músculo Esquelético/efeitos dos fármacos
Piperidinas/farmacologia
Pirazóis/farmacologia
Receptor CB1 de Canabinoide/antagonistas & inibidores
-Peso Corporal/efeitos dos fármacos
Canais de Cálcio Tipo L/efeitos dos fármacos
Canais de Cálcio Tipo L/metabolismo
Canais de Cálcio/metabolismo
Dieta Hiperlipídica/efeitos adversos
Intolerância à Glucose/etiologia
Resistência à Insulina
Camundongos Endogâmicos C57BL
Modelos Animais
Músculo Esquelético/metabolismo
Obesidade/etiologia
Receptor CB1 de Canabinoide/fisiologia
Limites: Animais
Masculino
Responsável: BR1.1 - BIREME


  8 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-780891
Autor: Fernandes, Caio Julio Cesar dos Santos; Alves Júnior, José Leonidas; Gavilanes, Francisca; Prada, Luis Felipe; Morinaga, Luciana Kato; Souza, Rogerio.
Título: New anticoagulants for the treatment of venous thromboembolism / Os novos anticoagulantes no tratamento do tromboembolismo venoso
Fonte: J. bras. pneumol;42(2):146-154, Mar.-Apr. 2016. tab, graf.
Idioma: en.
Resumo: Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.

O tromboembolismo venoso (TEV) está entre as principais causas de morte por doenças cardiovasculares no mundo, atrás apenas do infarto agudo do miocárdio e do acidente vascular cerebral. O TEV possui espectro de apresentação que vai desde a trombose venosa profunda até o tromboembolismo pulmonar agudo, de acordo com gravidade crescente de acometimento, sendo seu tratamento baseado na anticoagulação plena dos pacientes. Há muitas décadas, sabe-se que a anticoagulação interfere diretamente na mortalidade associada ao TEV. Até o início deste século a terapia anticoagulante se baseava no uso de heparina, em suas formas não fracionada ou de baixo peso molecular, e de antagonistas da vitamina K, principalmente a varfarina. Ao longo das últimas décadas, foram desenvolvidos novas classes de medicamentos anticoagulantes, inibidores do fator Xa e inibidores diretos da trombina, que mudaram significativamente o arsenal terapêutico do TEV, em função de suas características de eficácia e segurança em relação ao tratamento convencional, sendo o foco principal de esta revisão avaliar seu papel neste contexto clínico.
Descritores: Anticoagulantes/uso terapêutico
Tromboembolia Venosa/tratamento farmacológico
-Dabigatrana/uso terapêutico
Pirazóis/uso terapêutico
Piridinas/uso terapêutico
Piridonas/uso terapêutico
Rivaroxabana/uso terapêutico
Tiazóis/uso terapêutico
Fatores de Tempo
Varfarina/uso terapêutico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  9 / 52 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-751384
Autor: Soares, Wuber J. S.; Lima, Camila A.; Bilton, Tereza L.; Ferrioli, Eduardo; Dias, Rosângela C.; Perracini, Monica R..
Título: Association among measures of mobility-related disability and self-perceived fatigue among older people: a population-based study
Fonte: Braz. j. phys. ther. (Impr.) = Rev. bras. fisioter;19(3):194-200, May-Jun/2015. tab, graf.
Idioma: en.
Projeto: Conselho Nacional de Desenvolvimento Científico e Tecnológico; . FAPEMAT.
Resumo: Objective: To investigate the relationship between self-perceived fatigue with different physical functioning tests and functional performance scales used for evaluating mobility-related disability among community-dwelling older persons. Method: This is a cross-sectional, population-based study. The sample was composed of older persons with 65 years of age or more living in Cuiabá, MT, and Barueri, SP, Brazil. The data for this study is from the FIBRA Network Study. The presence of self-perceived fatigue was assessed using self-reports based on the Center for Epidemiologic Studies-Depression Scale. The Lawton instrumental activities of daily living scale (IADL) and the advanced activities of daily living scale (AADL) were used to assess performance and participation restriction. The following physical functioning tests were used: five-step test (FST), the Short Physical Performance Battery (SPPB), and usual gait speed (UGS). Three models of logistic regression analysis were conducted, and a significance level of α<0.05 was adopted. Results: The sample was composed of 776 older adults with a mean age (SD) of 71.9 (5.9) years, of whom the majority were women (74%). The prevalence of self-perceived fatigue within the participants was 20%. After adjusting for covariates, SPPB, UGS, IADL, and AADL remained associated with self-perceived fatigue in the final multivariate regression model. Conclusion: Our results suggest that there is an association between self-perceived fatigue and lower extremity function, usual gait speed and activity limitation and participation restriction in older adults. Further cohort studies are needed to investigate which physical performance measure may be able to predict the negative impact of fatigue in older adults. .
Descritores: Adenocarcinoma/genética
Carcinoma Pulmonar de Células não Pequenas/genética
Rearranjo Gênico
Neoplasias Pulmonares/genética
Inibidores de Proteínas Quinases/uso terapêutico
Pirazóis/uso terapêutico
Piridinas/uso terapêutico
Receptores Proteína Tirosina Quinases/genética
-Adenocarcinoma/metabolismo
Adenocarcinoma/secundário
Carcinoma Pulmonar de Células não Pequenas/metabolismo
Carcinoma Pulmonar de Células não Pequenas/secundário
Técnicas Imunoenzimáticas
Hibridização in Situ Fluorescente
Neoplasias Pulmonares/metabolismo
Neoplasias Pulmonares/patologia
Prognóstico
Reação em Cadeia da Polimerase em Tempo Real
Reação em Cadeia da Polimerase Via Transcriptase Reversa
RNA Mensageiro/genética
Receptores Proteína Tirosina Quinases/metabolismo
Limites: Adulto
Humanos
Masculino
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  10 / 52 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Venezuela
Texto completo
Id: lil-740321
Autor: Diez-Ewald, María.
Título: Desde el apixaban hasta la aspirina, en la prevención del tromboembolismo venoso recurrente
Fonte: Invest. clín;54(3):231-233, sep. 2013.
Idioma: es.
Descritores: Anticoagulantes/uso terapêutico
Tromboembolia/prevenção & controle
Trombose Venosa/prevenção & controle
-Anticoagulantes/classificação
Anticoagulantes/farmacologia
Antitrombinas/farmacologia
Antitrombinas/uso terapêutico
Aspirina/uso terapêutico
Ensaios Clínicos como Assunto
Inibidores do Fator Xa
Heparina de Baixo Peso Molecular/uso terapêutico
Estudos Multicêntricos como Assunto
Pirazóis/uso terapêutico
Piridonas/uso terapêutico
Recidiva
Trombofilia/tratamento farmacológico
Vitamina K/antagonistas & inibidores
Limites: Humanos
Tipo de Publ: Editorial
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde